Role of protein tyrosine phosphatase-1B in diabetes and obesity.
Type 2 or non-insulin-dependent diabetes mellitus (NIDDM) is reaching epidemic proportions in industrialized countries. Obesity is a major factor in this disease, since about 75% of obese individuals will develop type 2 diabetes. There is an urgent need to develop new therapies for these diseases. Recently, the protein tyrosine phosphatase PTP-1B has been shown to be a negative regulator of the insulin signaling pathway, suggesting that inhibitors of this enzyme may be beneficial in the treatment of type 2 diabetes. Mice lacking PTP-1B are resistant to both diabetes and obesity.
Kennedy
B P
BP
Department of Biochemistry and Molecular Biology, Merck Frosst Center for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada.
D000818:Animals; D019049:Developed Countries; D003920:Diabetes Mellitus / Q000201:enzymology / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000503:physiopathology*; D017027:Protein Tyrosine Phosphatases / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
D017027:Protein Tyrosine Phosphatases